150
1
148
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T17218 |
Varespladib methyl
A-002,LY333013 |
Others; Phospholipase | Metabolism; Others |
Varespladib methyl (LY333013) 是 Varespladib 的生物可利用前药,是一种特异性 II 组分泌型磷脂酶 A2 抑制剂。 | |||
T8875 |
CD73-IN-3
EX-A4254,LY-3475070 |
CD73 | Immunology/Inflammation |
CD73-IN-3 (LY-3475070) 是一种有效的选择性 CD73 抑制剂,IC50 为 28 nM,具有癌症的研究潜力。 | |||
T9078 |
LY3405105
1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester |
CDK | Cell Cycle/Checkpoint |
LY3405105 (1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester) 是一种新型 CDK7 抑制剂。 | |||
T19638 |
LY-301664
LY301664,奥氮平相关物质B,LY 301664 |
Others | Others |
LY-301664 是一种具有生物活性的奥氮平(Olanzapine)杂质。 | |||
T4423 |
LY 303511 hydrochloride
LY303511 hydrochloride |
Potassium Channel; TNF; mTOR | Apoptosis; Membrane transporter/Ion channel; PI3K/Akt/mTOR signaling |
LY 303511 hydrochloride 是LY294002 的一种结构类似物。LY 303511 hydrochloride 可增强 SHEP-1 神经母细胞瘤细胞的TRAIL 敏感性,还可逆地阻断 MIN6 胰岛瘤细胞中的K+电流。 | |||
T22948 |
LY 272015 hydrochloride
|
Others | Others |
LY 272015 hydrochloride is a 5-HT2B receptor antagonist. | |||
T2344L |
LY 344864 racemate
|
5-HT Receptor | GPCR/G Protein; Neuroscience |
LY 344864 racemate 是一种 5-HT1F 受体激动剂。 | |||
T24421 |
LY-2624803
DB-7,LY2624803,HY-10275,LY 2624803 |
5-HT Receptor; Histamine Receptor | GPCR/G Protein; Immunology/Inflammation; Neuroscience |
LY-2624803 是一种 5-HT2A 受体拮抗剂和组胺受体反向激动剂,可用于改善慢波睡眠。 | |||
T27954 |
LY-402913
LY 402913,LY402913 |
MRP | Immunology/Inflammation |
LY-402913 是一种选择性多药耐药蛋白 (MRP1) 抑制剂。 | |||
TQ0116 |
LY 3000328
Cathepsin S inhibitor |
Cysteine Protease | Proteases/Proteasome |
LY 3000328 (Cathepsin S inhibitor) 是 Cathepsin S 的选择性抑制剂,抑制人和小鼠Cat S 的IC50分别为7.7,1.67 nM。 | |||
T6018 |
Zosuquidar trihydrochloride
唑喹达三盐酸盐,Zosuquidar (LY335979) 3HCl,RS 33295-198 trihydrochloride,RS 33295-198 (D06387) 3HCl,Zosuquidar 3HCl,LY-335979 trihydrochloride |
P-gp | Membrane transporter/Ion channel; Neuroscience |
Zosuquidar trihydrochloride (LY-335979 trihydrochloride) 是一种P-糖蛋白抑制剂,Ki 值为 59 nM。 | |||
T22956 |
LY 78335
1-(2,3-Dichlorophenyl)ethanamine hydrochloride |
Others | Others |
LY 78335 (1-(2,3-Dichlorophenyl)ethanamine hydrochloride) 是一种苯乙醇胺-N-甲基转移酶 (PNMT) 抑制剂。 | |||
T2048 |
LY-364947
LY 364947,HTS466284 |
MLK; Casein Kinase; TGF-beta/Smad; RIP kinase | Apoptosis; MAPK; Metabolism; NF-κB; Stem Cells |
LY-364947 (HTS466284) 是有效的、ATP 竞争性的TGFβR-I 抑制剂(IC50:59 nM),是对 TGFβR-II 选择性的 7 倍。 | |||
T22437 |
Tazofelone
LY-213829 |
Others | Others |
Tazofelone (LY-213829) 是环氧合酶-II (COX-II) 抑制剂。在 CYP3A 介导下,Tazofelone 可转化为亚砜和喹啉代谢物,可用于研究炎症性肠病。 | |||
T1746 |
LY-2584702 tosylate salt
LY2584702 tosylate |
S6 Kinase | MAPK; PI3K/Akt/mTOR signaling |
LY-2584702 tosylate salt 是一种选择性的 ATP 竞争性 p70S6K 抑制剂,IC50为 4 nM,对S6K1的IC50为 2 nM,用于研究癌症治疗的试验。 | |||
T0189 |
Pemetrexed
Pemetrexed acid,培美曲塞,LY231514,培美曲唑,LY-231514 Disodium Hydrate |
DHFR; DNA/RNA Synthesis; Antifolate; Autophagy | Autophagy; Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism |
Pemetrexed (LY-231514 Disodium Hydrate) acid 是一种鸟嘌呤衍生的抗肿瘤药物,可结合并抑制胸苷酸合酶、二氢叶酸还原酶和甘氨酰胺核苷酸甲酰转移酶的 Ki 分别为 1.3 nM、7.2 nM 和 65 nM。 | |||
TQ0082 |
Aticaprant
LY-2456302,CERC-501 |
Opioid Receptor | Endocrinology/Hormones; GPCR/G Protein; Neuroscience |
Aticaprant (LY-2456302) 是一种有效的中枢渗透性 kappa-阿片受体拮抗剂,Ki 值为 0.807 nM。 | |||
T68127 |
Picenadol
LY-150720,LY150720,LY 150720 |
Others | Others |
Picenadol (LY 150720) 是N-甲基-4-苯基哌啶衍生物的外消旋混合物,具有激动剂 - 拮抗剂阿片性质。Picenadol 具有中枢镇痛活性。 | |||
T0450 |
Fluoxetine
氟西汀,LY-110140 |
5-HT Receptor; Serotonin Transporter; MRP; Autophagy | Autophagy; GPCR/G Protein; Immunology/Inflammation; Neuroscience |
Fluoxetine (LY-110140) 是一种高度特异性的血清素摄取抑制剂,是选择性 5-羟色胺 (5-HT) 再吸收抑制剂。Fluoxetine 具有抗抑郁活性。 | |||
T6063 |
LY-411575
LY411575 |
Apoptosis; Gamma-secretase | Apoptosis; Neuroscience; Proteases/Proteasome; Stem Cells |
LY-411575 是一种高效的γ-secretase 抑制剂,能够抑制 Aβ40 蛋白的产生,在膜中的 IC50 为 0.078 nM,在细胞中为 0.082 nM。 它还抑制 Notch 切割,IC50 为 0.39 nM。 | |||
T6461 |
Dapoxetine hydrochloride
LY-210448,LY-210448 hydrochloride,Dapoxetine HCl,盐酸达泊西汀,Priligy |
5-HT Receptor; Serotonin Transporter | GPCR/G Protein; Neuroscience |
Dapoxetine hydrochloride (LY-210448 hydrochloride) 是一种具有口服活性的、选择性的血清素再摄取 (serotonin reuptake) 抑制剂 (SSRI),可用于研究早泄 (PE) 。 | |||
T15827 |
LY 345899
|
DHFR | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism |
LY 345899 是叶酸的类似物,也是亚甲基四氢叶酸脱氢酶 (MTHFD1;DC301) 和MTHFD2抑制剂,其IC50值分别为 96 nM 和 663 nM,对MTHFD1的Ki=为 18 nM。 | |||
T6069 |
Gemcitabine hydrochloride
Gemcitabine HCl,吉西他滨盐酸盐,Gemzar,LY188011,盐酸吉西他滨,LY 188011 hydrochloride |
Apoptosis; Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis; Autophagy | Apoptosis; Autophagy; Cell Cycle/Checkpoint; DNA Damage/DNA Repair |
Gemcitabine hydrochloride (LY 188011 hydrochloride) 是一种人工合成的胞嘧啶核苷衍生物,一种 DNA 合成抑制剂。Gemcitabine 具有抗肿瘤活性和抗代谢活性。Gemcitabine 可以引起细胞自噬和凋亡。 | |||
T29421 |
LY195448
4-(3-(2-Hydroxy-2-phenyl)ethylamino-3-methylbutyl)benzamide |
Others | Others |
LY 195448 (4-(3-(2-Hydroxy-2-phenyl)ethylamino-3-methylbutyl)benzamide) 是存在于人血液和尿液中的一种物质,在小鼠肿瘤模型中显示出抗肿瘤活性,可在中期阻断细胞。 | |||
T6202 |
DAPT
LY-374973,GSI-IX |
Apoptosis; Beta Amyloid; Gamma-secretase; Autophagy | Apoptosis; Autophagy; Neuroscience; Proteases/Proteasome; Stem Cells |
DAPT (LY-374973) 是一种 γ 分泌酶抑制剂,抑制总 Aβ 和 Aβ42 (IC50=115/200 nM),具有口服活性。DAPT 也是一种 Notch 抑制剂。DAPT 可以诱导细胞分化、诱导细胞自噬和凋亡。 | |||
T26619 |
Amitivir
LY217896,LY 217896,阿米替韦,LY-217896 |
Others; Influenza Virus | Microbiology/Virology; Others |
Amitivir (LY 217896) 是一种噻二唑衍生物,对 A 和 B 型流感病毒均有效,对正粘病毒和副粘病毒具有广泛的抗病毒活性。 | |||
TP1111 |
Tirzepatide
LY-3298176 |
Glucagon Receptor | GPCR/G Protein |
Tirzepatide (LY-3298176) 是葡萄糖依赖性多肽 (GIP) 和胰高血糖素样肽-1 (GLP-1) 受体双重激动剂,具有神经保护活性,可改善血压并降低低密度脂蛋白 (LDL) 胆固醇和甘油三酯,可以用于研究糖尿病和肥胖症。 | |||
T4079 |
LY-294002 hydrochloride
SF 1101,LY 294002,NSC 697286 |
PI3K | PI3K/Akt/mTOR signaling |
LY-294002 hydrochloride (NSC 697286) 是一种合成的 PI3Kα/δ/β 分子抑制剂(IC50:0.5/0.57/0.97 μM,在无细胞试验中);在溶液中比 Wortmannin 更稳定,也是自噬体形成的阻断剂。 | |||
T36640 |
Xanomeline
LY-246708 |
AChR | Neuroscience |
Xanomeline (LY-246708) 是一种功能性选择性 M1/M4激活剂,用于精神分裂等神经疾病的研究,在临床前试验中显示出良好的治疗前景。Xanomeline 口服吸收良好,通过血脑屏障,并与至少六种代谢物进行广泛的肝脏代谢。 | |||
T0189L |
Pemetrexed disodium
培美曲塞二钠盐,LY-231514,LY231514 disodium,培美曲塞二钠,Pemetrexed |
Apoptosis; DHFR; DNA/RNA Synthesis; Antifolate; Autophagy | Apoptosis; Autophagy; Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism |
Pemetrexed disodium (LY-231514) 是一种叶酸拮抗剂,用于治疗非小细胞肺癌和恶性间皮瘤。它抑制胸苷酸合成酶,二氢叶酸还原酶和甘氨酰胺核苷酸甲酰转移酶的Ki 分别为 1.3 nM,7.2 nM 和 65 nM。 | |||
T6226 |
Pemetrexed disodium hemipenta hydrate
培美曲塞二钠一水合物,Pemetrexed Disodium Hydrate,LY-231514 Disodium Hydrate,Pemetrexed sodium hydrate,培美曲塞二钠水合物 |
Apoptosis; DHFR; DNA/RNA Synthesis; Antifolate; Autophagy | Apoptosis; Autophagy; Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism |
Pemetrexed disodium hemipenta hydrate (LY-231514 Disodium Hydrate) 是一种叶酸拮抗剂。抑制胸苷酸合成酶 (TS),二氢叶酸还原酶 (DHFR) 和甘氨酰胺核苷酸甲酰转移酶 (GARFT),Ki 分别为 1.3 nM,7.2 nM 和 65 nM。 | |||
T6952 |
Prasugrel Hydrochloride
LY 640315,PCR 4099 (hydrochloride),盐酸普拉格雷,Effient Hydrochloride,LY 640315 Hydrochloride,Prasugrel HCl |
P2Y Receptor | GPCR/G Protein; Neuroscience |
Prasugrel Hydrochloride (LY 640315 Hydrochloride) 是一种噻吩吡啶和前药,是一种可口服的P2Y12受体拮抗剂,抑制 ADP 诱导的血小板聚集,用于预防急性冠状动脉综合征患者的血栓形成、不稳定型心绞痛和心肌梗塞,以及接受经皮冠状动脉介入治疗的患者。 | |||
T3689 |
Ruboxistaurin hydrochloride
Ruboxistaurin,LY333531 HCl,LY 333531 hydrochloride,芦布妥林 |
PKC | Chromatin/Epigenetic; Cytoskeletal Signaling |
Ruboxistaurin hydrochloride (LY 333531 hydrochloride) 是蛋白激酶 C(PKC) 的同工酶选择性抑制剂,竞争性且可逆地抑制 PKCβI 和 PKCβII,IC50 值分别为 4.7 和 5.9 nM。 | |||
T1242 |
Alvimopan
爱维莫潘 |
Opioid Receptor | Endocrinology/Hormones; GPCR/G Protein; Neuroscience |
Alvimopan (LY 246736) 是一种选择性和竞争性 μ 阿片受体拮抗剂,IC50值为 1.7 nM。它存在于肌间和黏膜下神经元以及人体肠道固有层的免疫细胞中,可用于术后肠梗阻的研究。 | |||
T0869 |
Atomoxetine hydrochloride
Tomoxetine hydrochloride,(R)-Tomoxetine hydrochloride,盐酸托莫西汀,LY 139603,Atomoxetine HCl,LY 139603 HCl |
Dopamine Receptor; 5-HT Receptor; Norepinephrine | GPCR/G Protein; Neuroscience |
Atomoxetine hydrochloride (LY 139603) 是苯氧基-3-丙胺衍生物和选择性非兴奋剂,是去甲肾上腺素再摄取抑制剂,具有认知增强活性。 与人 NET,SERT 和 DAT 的放射性配体结合的 Ki 分别为5,77和1451 nM。 | |||
T6159 |
LY-2584702 free base
|
S6 Kinase; mTOR | MAPK; PI3K/Akt/mTOR signaling |
LY-2584702 free base 是一种选择性的 ATP 竞争性 p70S6K 抑制剂,IC50为 4 nM,对S6K1的IC50为 2 nM,用于研究癌症治疗的试验。 | |||
T15826 |
Lometrexol
LY 264618,DDATHF |
DHFR | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism |
Lometrexol (LY 264618) 是一种抗嘌呤类抗叶酸 (Antifolate) 药,可抑制甘氨酰胺核糖核苷酸甲酰基转移酶 (GARFT) 的活性,但不会引起可检测水平的 DNA 链断裂。Lometrexol 可以进一步抑制嘌呤从头合成,导致异常的细胞增殖,凋亡 (Apoptosis) 和细胞周期停滞。Lometrexol 具有抗癌活性。Lometrexol 还是一种有效的人丝氨酸羟甲基转移酶 1/2 (hSHMT1/2) 抑制剂。 | |||
T33007 |
LY-221204
LY 221204,LY221204 |
||
LY-221204 is a bio-active chemical. | |||
T33004 |
LY 54761
LY-54761,LY54761 |
||
LY 54761 is a bio-active chemical. | |||
T33017 |
LY-426965 hydrochloride
|
||
LY-426965 hydrochloride is a bioactive chemical. | |||
T22944 |
LY 235959
|
Others | Others |
LY 235959 is a NMDA receptor antagonist. | |||
T33001 | LY 294619 | ||
LY 294619 is a bioactive hcemical. | |||
T32991 |
LY 175877
LY175877,LY-175877 |
||
LY 175877 is a bioactive chemical. | |||
T32999 |
LY 289612
|
||
LY 289612 is a bioactive chemical. | |||
T33008 |
LY-228729
|
||
LY-228729 is a bioactive chemical. | |||
T27892 |
LY 201409
LY201409,LY-201409 |
||
LY 201409 is a potent benzamide anticonvulsant. | |||
T32989 |
LY 163252
|
||
LY 163252 is a bio-active chemical. | |||
T27880 |
LY 170198
LY170198,LY-170198 |
||
LY 170198 is a protein kinase C inhibitor. | |||
T27922 |
LY 56110
LY56110,LY-56110 |
||
LY 56110 is a novel nonsteroidal aromatase inhibitor. | |||
T27874 |
LY 135305
LY-135305,LY135305 |
||
LY 135305 is a inhibition of spontaneous metastasis. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T75635 |
Microcystin-LY
|
||
Microcystin-LY 是一种铜绿微囊藻蓝藻的环状七肽毒素,可作为 Nrf2通路的激活剂引起氧化应激反应,在3μM 时诱导效果非常明显。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01334 |
CD5 Protein, Mouse, Recombinant (His)
Ly-A,Lyt-1,CD5 molecule,Ly |
Mouse | HEK293 Cells |
CD5 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 39.4 kDa and the accession number is P13379. | |||
TMPY-05544 |
LY6A Protein, Mouse, Recombinant (His)
Sca-1,lymphocyte antigen 6 comple... |
Mouse | E. coli |
LY6A Protein, Mouse, Recombinant (His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 10.9 kDa and the accession number is P05533. | |||
TMPY-02414 |
Klrb1a Protein, Mouse, Recombinant (His)
Nkrp1a,NKRP12,Nkrp1-a,ly-55A<... |
Mouse | HEK293 Cells |
Klrb1a Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 21 kDa and the accession number is P27811. | |||
TMPY-05133 |
CD86 Protein, Mouse, Recombinant (His), Biotinylated
Ly-58,ETC-1,B70,MB7,TS/A-2,Cd28l2,CLS1,CD8... |
Mouse | HEK293 Cells |
CD86 Protein, Mouse, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.7 kDa and the accession number is P42082-1. | |||
TMPY-01206 |
CD86 Protein, Mouse, Recombinant (His)
Cd28l2,CLS1,Ly58,Ly-58,B7,MB7,B7.2,MB7-2,E... |
Mouse | HEK293 Cells |
CD86 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.8 kDa and the accession number is P42082-1. | |||
TMPY-05386 |
CD86 Protein, Mouse, Recombinant (hFc)
Ly58,B7.2,ETC-1,B70,TS/A-2,CD86 a... |
Mouse | HEK293 Cells |
CD86 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 52 kDa and the accession number is P42082-1. | |||
TMPY-03999 |
MD2/LY96 Protein, Mouse, Recombinant (hFc)
lymphocyte antigen 96,ESOP-1,MD2,MD-2 |
Mouse | HEK293 Cells |
LY96 (Lymphocyte Antigen 96, also known as ESOP-1) is a Protein Coding gene. 2 alternatively spliced human isoforms have been reported. This gene encodes a protein that associates with toll-like receptor 4 on the cell surface and confers responsiveness to lipopolysaccharide (LPS), thus providing a link between the receptor and LPS signaling. LY-96 also cooperates with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria. It enhances the TLR4-dependent activa... | |||
TMPY-02440 |
SAP/SH2D1A Protein, Human, Recombinant (His)
XLPD,EBVS,DSHP,SAP,MTCP1,IMD5,SH2 domain c... |
Human | E. coli |
SH2domain-containing protein 1A (SH2D1A / SAP) is a 128 amino acid protein, containing a single Src homology 2 (SH2) domain, flanked by 5 amino acids at the N-terminus and 25 amino acids at the C-terminus. The absence of a catalytic domain and the presence of an SH2domain suggest that SH2D1A regulates one or more signal transduction pathways. SH2D1A interacts with signaling lymphocytic activation molecule (SLAM), which is a transmembrane protein expressed on the surface of activated T and B cell... | |||
TMPK-01426 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A*02:01,Peptide Ready,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01419 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01421 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
HLA-A*02:01,MHC,Peptide Ready |
Human | HEK293 Cells |
HLA-A*02:01&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01420 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01422 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01425 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01410 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A,MHC,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01409 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Peptide Ready,MHC,HLA-A |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01415 |
APC-equivalent Peptide Ready HLA-A*02:01&B2M Tetramer Protein, Human, MHC (His)
Peptide Ready,HLA-A*02:01,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Tetramer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01403 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
K-Ras 2,KI-RAS,CFC2,KRAS1,GTP... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01448 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein, Human, MHC (E. coli, His & Avi)
MHC,LAGE-2,NY-ESO-1,ESO1CTAG,MY-ESO-1,CT |
Human | E. coli |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01427 |
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
C-K-RAS,K-RAS4B,GTPase Kra |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01399 |
HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS2A,NS3,KRAS2,CFC2,K-RA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01404 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
NS,KRAS,KRAS1,KRAS2,MHC,RA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01467 |
HLA-A*02:01&B2M&HPV 16 E6 (KLPQLCTEL) Monomer Protein, Human, MHC (His & Avi)
HPV16,E6,Human papillomavirus typ... |
Human | HEK293 Cells |
Human papillomavirus (HPV) 16 infection is a necessary condition for the pathogenesis and development of cervical cancer. The E6 protein is expressed by the HPV16 E6 gene and promotes malignant phenotype transformation, which is an important mechanism for the occurrence and development of cervical cancer. | |||
TMPK-01479 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
NS3,KRAS1,K-Ras 2,K-RAS2A |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01520 |
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein, Human, MHC (His & Avi)
Alpha-1-fetoprotein,AFP,HPA |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01474 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi)
|
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01444 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Tetramer Protein, Human, MHC (His & Avi)
MZ2-E,MAGE1A,MAGE-1 anti... |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01461 |
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KRAS,RASK2,K-Ras... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01470 |
HLA-A*02:01&B2M&MAGE-A4 or MAGE-A8 (KVLEHVVRV) Monomer Protein, Human, MHC (His & Avi)
MAGE-A4 or MAGE-A8,M... |
Human | HEK293 Cells |
MAGE-A4 and MAGE-A8 are type I membes of the melanoma associated antigen (MAGE) family. The MAGE family is a large, highly conserved group of proteins that share a common MAGE homology domain. Both MAGE-A4 and MAGE-A8 antigen-presenting peptides can be presented by HLA-A*02:01. | |||
TMPK-01525 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01434 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,CFC2,GTPase Kras,KRA |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01417 |
HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
Alpha-1-fetoprotein,HPAFP,A |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01446 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi)
MAGE1,MAGE1A,MAGE-1 ... |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01481 |
HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
svn 2B,svn-2B,Survivin-2B |
Human | HEK293 Cells |
Survivin-2B, a known splice variant of survivin, has been reported to promote cell death in some cancer cells, although it keeps prosurvival function in others.survivin-2B promoted autophagy and further regulated cell death by accumulating and stabilizing IKK alpha in the nucleus. | |||
TMPK-01494 |
HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein, Human, MHC (His & Avi)
HLA-A,HLA-A*0101,HLA... |
Human | HEK293 Cells |
Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. | |||
TMPK-01519 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi)
MHC,FETA,AFP,Alpha-feto,... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01530 |
HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,LMP-2,PSMB9,LMP2,Macropain cha |
Human | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01513 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT6.1,LAGE2A,MHC,CTAG1B,CTA |
Human | HEK293 Cells |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01408 |
HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
RALD,KRAS1,KRAS2,K-RAS2B... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01401 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CFC2,K-Ras 2,RALD,K-RAS4A... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01429 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
MHC,K-Ras 2,NS,K-RAS4A,KRA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01449 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CT6.1,CTAG1,LAGE-2,MY-ESO-1,NY-ESO-1,E... |
Human | E. coli |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01473 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.3,MAGE-3,MZ2-D,MZ2D,HLA-A2402... |
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01488 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,MHC,GTPase Kras,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01445 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.1,MAGE1,MAGE-1,MAGE-A |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01529 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,KRAS1,MHC,K-RAS2... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01455 |
HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein, Human, MHC (His & Avi)
OIP4,PRAME,OIP-4,MAPE |
Human | HEK293 Cells |
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. | |||
TMPK-01458 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,GTPase Kras,KRAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01463 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KI-RAS,KRAS1,K-RA |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01477 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
HPAFP,FETA,Alpha-1-fetop... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
------------------------ 更多 ------------------------ |